Physician profile
Leroy E Schaefer
NPI 1902869332
$9,754.54
in general payments reported to CMS, 2019-2025
47 companies · $2,031 in 2025
The $2,031 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $729 · 2021: $1,462 · 2022: $1,479 · 2023: $1,393 · 2024: $1,684 · 2025: $2,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,107.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,264.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $964.10 | 2020-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $804.67 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $686.04 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $665.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $494.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $440.23 | 2019-2025 | Repatha, Repatha, Otezla |
| Mylan Specialty L.P. | $378.04 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $350.84 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $274.26 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.54 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $238.99 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $223.05 | 2019-2025 | |
| Abbott Laboratories | $208.78 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.34 | 2020-2024 | Jardiance |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $200.65 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $193.31 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.63 | 2023-2025 | Caplyta |
| Amarin Pharma, INC. | $162.00 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $155.23 | 2021-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $150.81 | 2019-2023 | Livalo, Seglentis |
| Sumitomo Pharma America, INC. | $140.30 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $127.77 | 2019-2022 | |
| Axsome Therapeutics, INC. | $117.50 | 2023-2025 | Auvelity |
| Viatris Specialty LLC | $116.04 | 2025 | Yupelri |
| Exact Sciences Corporation | $90.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $81.06 | 2022 | |
| Eisai INC. | $79.57 | 2020-2022 | |
| Allergan, INC. | $63.63 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $61.53 | 2020-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $56.00 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $34.71 | 2024 | Voquezna |
| Nevro Corp. | $32.97 | 2021-2023 | Senza |
| Dexcom, INC. | $31.06 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $29.83 | 2025 | Inspire |
| Lundbeck LLC | $29.46 | 2023 | Rexulti |
| Csl Behring | $28.72 | 2025 | Andembry |
| Shire North American Group INC | $26.02 | 2019 | |
| Medtronic, INC. | $24.07 | 2025 | Minimed 780g |
| Vertex Pharmaceuticals Incorporated | $18.52 | 2025 | |
| Biogen, INC. | $14.66 | 2020 | |
| Kci USA, INC. | $14.13 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.05 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.83 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.56 | 2021 | |
| Adlon Therapeutics L.P. | $11.70 | 2021 | |
| Corium, LLC | $10.48 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leroy Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.